Abbott Receives FDA Approval for Five-Minute Coronavirus Test
Abbott wins emergency FDA authorization for a rapid molecular COVID-19 test that delivers positive results in just five minutes. The portable device allows testing outside traditional hospitals in clinics and physician offices.
Abbott receives emergency use authorization from the FDA for the fastest available molecular point-of-care test for the novel coronavirus. The new ID NOW COVID-19 test delivers positive results in as little as five minutes and negative results in 13 minutes, significantly speeding up the diagnostic process.
The test runs on Abbott's ID NOW platform, a lightweight box that weighs just 6.6 pounds and is the size of a small toaster. This compact design allows the technology to operate outside the four walls of a traditional hospital in non-traditional settings like physician offices and urgent care clinics.
Abbott ramps up production to deliver 50,000 ID NOW COVID-19 tests per day to the U.S. healthcare system. This rapid testing capability provides a critical new tool to combat the spread of the novel coronavirus by enabling immediate results at the point of care.